Tianjin Hankang Pharmaceutical Biotechnology

Tianjin Hankang Pharmaceutical Biotechnology is a comprehensive pharmaceutical R&D and service company based in Tianjin, China. Founded in 2001, it operates as a major Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), providing services ranging from drug design and synthesis to clinical trial management. The company specializes in the development of high-end generic drugs and innovative small molecule therapeutics across various therapeutic areas, including oncology, cardiovascular, and metabolic health. In 2018, it was acquired by Jointown Pharmaceutical Group, one of China's largest pharmaceutical distributors, for approximately 1.5 billion RMB. This acquisition integrated Hankang's R&D expertise with Jointown's extensive supply chain and distribution network. Hankang maintains state-of-the-art R&D centers and GMP-compliant manufacturing facilities to support its domestic and international partners.